Dr. Dimiter S. Dimitrov

Abound Bio is a biotechnology company specializing in the discovery and development of next-generation antibody-based therapeutics, including CAR-T cell therapies and monoclonal antibodies. Founded in 2019 by world-renowned antibody engineer Dr. Dimiter Dimitrov and Dr. John Mellors, the company utilizes its proprietary, large-scale human antibody libraries to identify potent binders in various formats such as VH domains and scFvs. In June 2022, Abound Bio was acquired by Galapagos NV for $14 million to bolster its CAR-T pipeline and antibody discovery capabilities. The company maintains a strategic collaboration with Vor Bio to develop multi-targeted CAR-T treatments for hematologic malignancies and is advancing programs targeting CEACAM5, ENPP1, and HPK1.